Organigram Global Inc.

OGI Healthcare Drug Manufacturers Specialty & Generic

Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024. In the quarter to June 2026, revenue grew 49.3%, EPS grew 1,966.7% and free cash flow fell 192.3%, each against the same quarter a year earlier.

0.93 0.00 0.00%
Market cap
$131.4M
P/E
2.0×
Fwd P/E
11.4×
Dividend yield
—
F-score
5/9
Altman Z
0.22
Beneish M
−1.82
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
2.19 0.00 12.00 0.00

+8 more quarters

P/S ratio
0.62 0.89 1.13 1.40
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(46.67) (34.48) (19.73) (262.25)
P/B ratio
0.39 0.65 0.86 1.04
EV/Sales
0.65 0.69 0.91 1.07
EV/EBITDA
15.62 0.00 20.89 104.00
EV/FCF
(6.84) (8.68) (6.88) (11.34)
Current Ratio
2.61 2.82 2.73 2.26
Net Debt/EBITDA
0.61 3.69 (40.31) (7.69)
Debt/Equity
0.04 0.00 0.00 0.00
Earnings Yield
45.58% (9.34%) 8.33% (5.42%)
Free Cash Flow Yield
(15.34%) (8.91%) (11.64%) (6.77%)
Free Cash Flow per Share
(0.02) (0.04) (0.10) 0.00
Book value per Share
2.59 2.06 1.96 1.95
Free Cash Flow
(2.63) (5.32) (13.00) (0.22)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates